JP2020073561A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020073561A5 JP2020073561A5 JP2020001139A JP2020001139A JP2020073561A5 JP 2020073561 A5 JP2020073561 A5 JP 2020073561A5 JP 2020001139 A JP2020001139 A JP 2020001139A JP 2020001139 A JP2020001139 A JP 2020001139A JP 2020073561 A5 JP2020073561 A5 JP 2020073561A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- oxo
- dihydro
- phenoxyphenyl
- imidazo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170547P | 2015-06-03 | 2015-06-03 | |
| US62/170,547 | 2015-06-03 | ||
| US201562271689P | 2015-12-28 | 2015-12-28 | |
| US62/271,689 | 2015-12-28 | ||
| JP2017562758A JP6646072B2 (ja) | 2015-06-03 | 2016-06-02 | チロシンキナーゼ阻害剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562758A Division JP6646072B2 (ja) | 2015-06-03 | 2016-06-02 | チロシンキナーゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020073561A JP2020073561A (ja) | 2020-05-14 |
| JP2020073561A5 true JP2020073561A5 (2) | 2020-07-09 |
| JP6985433B2 JP6985433B2 (ja) | 2021-12-22 |
Family
ID=56118090
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562758A Active JP6646072B2 (ja) | 2015-06-03 | 2016-06-02 | チロシンキナーゼ阻害剤 |
| JP2020001139A Active JP6985433B2 (ja) | 2015-06-03 | 2020-01-08 | チロシンキナーゼ阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562758A Active JP6646072B2 (ja) | 2015-06-03 | 2016-06-02 | チロシンキナーゼ阻害剤 |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US20180162861A1 (2) |
| EP (3) | EP4112618A1 (2) |
| JP (2) | JP6646072B2 (2) |
| KR (3) | KR102552653B1 (2) |
| CN (2) | CN106459049B (2) |
| AU (2) | AU2016270973B2 (2) |
| CA (1) | CA2987335A1 (2) |
| CL (2) | CL2017003073A1 (2) |
| CO (1) | CO2017012947A2 (2) |
| CR (1) | CR20170593A (2) |
| DK (1) | DK3303334T3 (2) |
| DO (1) | DOP2017000279A (2) |
| EA (1) | EA039006B1 (2) |
| ES (1) | ES2878030T3 (2) |
| HK (1) | HK1252378A1 (2) |
| HR (1) | HRP20211249T1 (2) |
| HU (1) | HUE055419T2 (2) |
| IL (2) | IL255946A (2) |
| LT (1) | LT3303334T (2) |
| MX (2) | MX383213B (2) |
| MY (1) | MY190548A (2) |
| PE (1) | PE20180521A1 (2) |
| PH (2) | PH12021551681A1 (2) |
| PL (1) | PL3303334T3 (2) |
| PT (1) | PT3303334T (2) |
| RS (1) | RS62290B1 (2) |
| SG (1) | SG10201912443XA (2) |
| SI (1) | SI3303334T1 (2) |
| TN (1) | TN2017000501A1 (2) |
| TW (2) | TWI810582B (2) |
| UA (1) | UA124090C2 (2) |
| WO (1) | WO2016196840A1 (2) |
| ZA (2) | ZA201708667B (2) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104159635B (zh) | 2012-02-27 | 2018-09-25 | 奥雷制药有限公司 | 用于耳蜗内递送治疗剂以治疗耳部病症的固体药物植入物 |
| SI2892900T1 (en) | 2012-09-10 | 2018-01-31 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
| CN105764814B (zh) | 2013-11-29 | 2019-02-19 | 株式会社大造 | 内容物收容容器、使用其的内容物收容制品、排出制品及排出装置 |
| CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
| SG11201704808VA (en) | 2014-12-18 | 2017-07-28 | Principia Biopharma Inc | Treatment of pemphigus |
| UA124090C2 (uk) * | 2015-06-03 | 2021-07-21 | Прінсіпіа Байофарма Інк. | Інгібітори тирозинкінази |
| WO2016210165A1 (en) | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CN105753863B (zh) * | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| EP3414234B1 (en) * | 2015-10-14 | 2022-06-29 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
| CN115054586B (zh) | 2016-06-29 | 2024-08-02 | 普林斯匹亚生物制药公司 | 改性的释放制剂 |
| US10683292B2 (en) * | 2016-07-25 | 2020-06-16 | Nerviano Medical Sciences S.R.L. | Purine and 3-deazapurine analogues as choline kinase inhibitors |
| US10314844B2 (en) * | 2017-02-24 | 2019-06-11 | Gilead Sciences, Inc. | Inhibitors of Bruton's tyrosine kinase |
| WO2019208805A1 (ja) * | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
| KR20210038877A (ko) | 2018-07-25 | 2021-04-08 | 노파르티스 아게 | Nlrp3 인플라마좀 억제제 |
| CN117285467A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| CA3106385A1 (en) * | 2018-09-13 | 2020-03-19 | Kissei Pharmaceutical Co., Ltd. | Imidazopyridinone compound |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| US20210106584A1 (en) | 2019-10-14 | 2021-04-15 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| CN113045484B (zh) * | 2019-12-27 | 2024-01-26 | 南京药石科技股份有限公司 | 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法 |
| CN113149891B (zh) * | 2020-01-07 | 2024-02-02 | 南京药石科技股份有限公司 | 一种2-氨基-2-（1-甲基-4-哌啶基）乙醇的制备方法 |
| BR112022014058A2 (pt) | 2020-01-20 | 2022-09-13 | Genzyme Corp | Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms) |
| US11814390B2 (en) | 2020-01-22 | 2023-11-14 | Principia Biopharma Inc. | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| MX2022012248A (es) * | 2020-03-30 | 2022-10-27 | Igia Pharmaceuticals Inc | Formulacion pediatrica de inhibidores de tirosina quinasa. |
| WO2022033460A1 (zh) * | 2020-08-10 | 2022-02-17 | 江苏恒瑞医药股份有限公司 | Btk抑制剂治疗疾病的用途 |
| JP7545570B2 (ja) | 2020-08-14 | 2024-09-04 | ノバルティス アーゲー | ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用 |
| US12064421B2 (en) | 2020-11-02 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors |
| AU2021398051A1 (en) | 2020-12-10 | 2023-07-27 | Principia Biopharma Inc. | Crystal form of tolebrutinib, preparation method therefor and use thereof |
| US20240051955A1 (en) * | 2020-12-23 | 2024-02-15 | Genzyme Corporation | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof |
| CN116710452A (zh) * | 2020-12-23 | 2023-09-05 | 建新公司 | 4-氨基-3-(4-苯氧基苯基)-1,3-二氢-2h-咪唑并[4,5-c]吡啶-2-酮衍生物及其盐类 |
| EP4313023A1 (en) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
| US20240217973A1 (en) * | 2021-04-16 | 2024-07-04 | Medshine Discovery Inc. | Imidazopyridine compounds and use thereof |
| EP4328226A4 (en) | 2021-04-23 | 2025-08-27 | Hangzhou Solipharma Co Ltd | CRYSTALLINE FORM, AMORPHOUS FORM OF TOLEBRUTINIB, PREPARATION PROCESS THEREOF AND USE THEREOF |
| CN117412749A (zh) | 2021-05-21 | 2024-01-16 | 杭州领业医药科技有限公司 | Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途 |
| WO2022257845A1 (zh) | 2021-06-11 | 2022-12-15 | 苏州科睿思制药有限公司 | Tolebrutinib的晶型及其制备方法和用途 |
| WO2023280132A1 (zh) * | 2021-07-06 | 2023-01-12 | 苏州晶云药物科技股份有限公司 | 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法 |
| US11793820B2 (en) * | 2021-09-24 | 2023-10-24 | Chadwick Donaldson | Dry powder foamable formulations for delivery of medicaments through the mucosa |
| US20250145618A1 (en) | 2021-12-21 | 2025-05-08 | Principia Biopharma Inc. | Crystalline Forms of (R)-1-(1-Acryloylpiperidin-3-YL)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One and salts Thereof |
| WO2023172663A1 (en) * | 2022-03-09 | 2023-09-14 | Teva Pharmaceuticals International Gmbh | Solid state forms of tolebrutinib and of tolebrutinib salts |
| US20230399313A1 (en) * | 2022-06-10 | 2023-12-14 | Advenchen Pharmaceuticals, LLC | Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers |
| EP4540229A1 (en) * | 2022-06-14 | 2025-04-23 | Principia Biopharma Inc. | Methods of making tolebrutinib |
| CA3259743A1 (en) * | 2022-06-22 | 2023-12-28 | Principia Biopharma Inc. | METHODS FOR MANUFACTURING MODIFIED BTK INHIBITORS |
| CA3260159A1 (en) | 2022-06-30 | 2024-01-04 | Principia Biopharma Inc. | Therapeutic Tyrosine Kinase Inhibitors for the Treatment of Multiple Sclerosis and Myasthenia Gravis |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| EP4601647A1 (en) | 2022-10-11 | 2025-08-20 | Principia Biopharma Inc. | Therapeutic tyrosine kinase inhibitors for multiple sclerosis |
| WO2024099242A1 (zh) * | 2022-11-07 | 2024-05-16 | 天津征程医药科技有限公司 | 氘代的氨基吡啶衍生物以及包含该化合物的药物组合物 |
| AU2023408758A1 (en) | 2022-12-20 | 2025-07-31 | Principia Biopharma Inc. | Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4- phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one |
| JP2026505764A (ja) | 2023-02-01 | 2026-02-18 | プリンシピア バイオファーマ インコーポレイテッド | 多発性硬化症を診断及び治療する方法 |
| US20250282777A1 (en) | 2024-03-06 | 2025-09-11 | Principia Biopharma Inc. | Methods of Making Tolebrutinib |
| WO2026050513A1 (en) | 2024-08-30 | 2026-03-05 | Principia Biopharma Inc. | Tolebrutinib for multiple sclerosis |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
| DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
| US3760984A (en) | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US3952741A (en) | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
| US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
| US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| CA2465328C (en) | 2001-11-01 | 2011-06-14 | Michael Francis Gross | Piperidines |
| US20060045822A1 (en) | 2004-09-01 | 2006-03-02 | Board Of Regents, The University Of Texas System | Plasma polymerization for encapsulating particles |
| CN101056877B (zh) * | 2004-09-14 | 2010-06-09 | 诺华疫苗和诊断公司 | 咪唑并喹啉化合物 |
| AU2006213746A1 (en) * | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods |
| EP2700638A1 (en) | 2006-05-31 | 2014-02-26 | The Regents Of the University of California | Purine analogs |
| TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| US9556426B2 (en) | 2009-09-16 | 2017-01-31 | Celgene Avilomics Research, Inc. | Protein kinase conjugates and inhibitors |
| US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| TWI500617B (zh) * | 2010-05-31 | 2015-09-21 | Ono Pharmaceutical Co | Purine ketone derivatives |
| CN103502249A (zh) * | 2011-05-17 | 2014-01-08 | 普林斯匹亚生物制药公司 | 作为酪氨酸激酶抑制剂的氮杂吲哚衍生物 |
| ES2770550T3 (es) * | 2011-05-17 | 2020-07-02 | Univ California | Inhibidores de quinasa |
| PL2710005T3 (pl) * | 2011-05-17 | 2017-07-31 | Principia Biopharma Inc. | Inhibitory kinazy tyrozynowej |
| US9199997B2 (en) * | 2011-11-29 | 2015-12-01 | Ono Pharmaceutical Co., Ltd. | Purinone derivative hydrochloride |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| WO2013191965A1 (en) | 2012-06-18 | 2013-12-27 | Principia Biopharma Inc. | Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases |
| SG11201500125QA (en) | 2012-07-11 | 2015-02-27 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| SI2892900T1 (en) * | 2012-09-10 | 2018-01-31 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
| US20140142099A1 (en) * | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
| US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| UA124090C2 (uk) * | 2015-06-03 | 2021-07-21 | Прінсіпіа Байофарма Інк. | Інгібітори тирозинкінази |
| CN105753863B (zh) | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| EP3414234B1 (en) | 2015-10-14 | 2022-06-29 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
-
2016
- 2016-06-02 UA UAA201712794A patent/UA124090C2/uk unknown
- 2016-06-02 EP EP22188609.6A patent/EP4112618A1/en active Pending
- 2016-06-02 PL PL16728566T patent/PL3303334T3/pl unknown
- 2016-06-02 PE PE2017002512A patent/PE20180521A1/es unknown
- 2016-06-02 SG SG10201912443XA patent/SG10201912443XA/en unknown
- 2016-06-02 RS RS20211083A patent/RS62290B1/sr unknown
- 2016-06-02 TN TNP/2017/000501A patent/TN2017000501A1/en unknown
- 2016-06-02 HK HK18111674.0A patent/HK1252378A1/zh unknown
- 2016-06-02 TW TW110121130A patent/TWI810582B/zh active
- 2016-06-02 ES ES16728566T patent/ES2878030T3/es active Active
- 2016-06-02 MX MX2017015470A patent/MX383213B/es unknown
- 2016-06-02 EP EP21169631.5A patent/EP3912979B1/en active Active
- 2016-06-02 KR KR1020177037609A patent/KR102552653B1/ko active Active
- 2016-06-02 KR KR1020227035399A patent/KR102666352B1/ko active Active
- 2016-06-02 SI SI201631244T patent/SI3303334T1/sl unknown
- 2016-06-02 MY MYPI2017704576A patent/MY190548A/en unknown
- 2016-06-02 PH PH1/2021/551681A patent/PH12021551681A1/en unknown
- 2016-06-02 PT PT167285667T patent/PT3303334T/pt unknown
- 2016-06-02 DK DK16728566.7T patent/DK3303334T3/da active
- 2016-06-02 TW TW105117466A patent/TWI732765B/zh active
- 2016-06-02 KR KR1020247015612A patent/KR20240070721A/ko active Pending
- 2016-06-02 EA EA201792529A patent/EA039006B1/ru unknown
- 2016-06-02 HR HRP20211249TT patent/HRP20211249T1/hr unknown
- 2016-06-02 CN CN201680000891.8A patent/CN106459049B/zh active Active
- 2016-06-02 CA CA2987335A patent/CA2987335A1/en active Pending
- 2016-06-02 MX MX2021006571A patent/MX395007B/es unknown
- 2016-06-02 WO PCT/US2016/035588 patent/WO2016196840A1/en not_active Ceased
- 2016-06-02 PH PH1/2017/502203A patent/PH12017502203B1/en unknown
- 2016-06-02 CR CR20170593A patent/CR20170593A/es unknown
- 2016-06-02 US US15/578,623 patent/US20180162861A1/en not_active Abandoned
- 2016-06-02 JP JP2017562758A patent/JP6646072B2/ja active Active
- 2016-06-02 AU AU2016270973A patent/AU2016270973B2/en active Active
- 2016-06-02 LT LTEPPCT/US2016/035588T patent/LT3303334T/lt unknown
- 2016-06-02 HU HUE16728566A patent/HUE055419T2/hu unknown
- 2016-06-02 EP EP16728566.7A patent/EP3303334B1/en active Active
- 2016-06-02 CN CN202011284728.3A patent/CN113149983B/zh active Active
-
2017
- 2017-01-19 US US15/410,716 patent/US9688676B2/en active Active
- 2017-11-27 IL IL255946A patent/IL255946A/en active IP Right Grant
- 2017-12-01 CL CL2017003073A patent/CL2017003073A1/es unknown
- 2017-12-01 DO DO2017000279A patent/DOP2017000279A/es unknown
- 2017-12-15 CO CONC2017/0012947A patent/CO2017012947A2/es unknown
- 2017-12-19 ZA ZA2017/08667A patent/ZA201708667B/en unknown
-
2019
- 2019-07-31 CL CL2019002150A patent/CL2019002150A1/es unknown
-
2020
- 2020-01-08 JP JP2020001139A patent/JP6985433B2/ja active Active
- 2020-05-26 AU AU2020203447A patent/AU2020203447B2/en active Active
- 2020-09-23 US US17/029,184 patent/US20210171526A1/en not_active Abandoned
- 2020-12-07 IL IL279258A patent/IL279258B/en unknown
-
2022
- 2022-10-27 US US17/974,613 patent/US20230151012A1/en not_active Abandoned
-
2024
- 2024-02-13 ZA ZA2024/01324A patent/ZA202401324B/en unknown
- 2024-11-26 US US18/960,997 patent/US20250197402A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020073561A5 (2) | ||
| JP6776399B2 (ja) | ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用 | |
| JP2025508703A5 (2) | ||
| JP6586098B2 (ja) | キナーゼ阻害剤としてのピラゾリル尿素 | |
| US7642263B2 (en) | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | |
| JP6218260B2 (ja) | Ｊａｋ阻害剤としてのアミノピリミジニル化合物 | |
| US8329711B2 (en) | Pyridone-substituted-dihydropyrazolopyrimidinone derivative | |
| US7745475B2 (en) | Heteroaryl benzamide derivatives as GLK activators | |
| US20100160286A1 (en) | Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes | |
| JP2019504821A5 (2) | ||
| JP2009541268A5 (2) | ||
| US20110053910A1 (en) | 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes | |
| CA2677572A1 (en) | 3-amino-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives as pkc inhibitors | |
| US20230092892A1 (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| TW201725202A (zh) | 新穎經取代吲唑、其製法、包含其之醫藥製劑及其製備藥劑之用途 | |
| CN107257686A (zh) | 天疱疮的治疗 | |
| JP2017052805A5 (2) | ||
| HUE026041T2 (en) | Pyrrolo-triazinone derivatives as P13K inhibitors | |
| JP2009513575A5 (2) | ||
| US7655652B2 (en) | Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation | |
| JP2015527401A5 (2) | ||
| RU2014152257A (ru) | Гетероциклильные пиримидиновые аналоги в качестве ингибиторов tyk2 | |
| JP2022521380A5 (2) | ||
| JP6983945B2 (ja) | 自己免疫性疾患の処置 | |
| JP2019521167A5 (2) |